The Oncology Institute, Inc. $TOI Stake Lowered by Tiff Advisory Services LLC

Tiff Advisory Services LLC cut its stake in The Oncology Institute, Inc. (NASDAQ:TOI) by 76.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 856,628 shares of the company’s stock after selling 2,777,837 shares during the quarter. Oncology Institute makes up 0.6% of Tiff Advisory Services LLC’s portfolio, making the stock its 18th biggest holding. Tiff Advisory Services LLC owned 0.92% of Oncology Institute worth $2,990,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Balyasny Asset Management L.P. grew its stake in Oncology Institute by 17.3% in the second quarter. Balyasny Asset Management L.P. now owns 2,518,337 shares of the company’s stock valued at $5,163,000 after purchasing an additional 371,005 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Oncology Institute during the 2nd quarter valued at about $3,028,000. Geode Capital Management LLC grew its stake in shares of Oncology Institute by 231.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company’s stock valued at $2,623,000 after buying an additional 893,696 shares in the last quarter. Massar Capital Management LP increased its holdings in Oncology Institute by 300.0% in the second quarter. Massar Capital Management LP now owns 400,000 shares of the company’s stock worth $820,000 after buying an additional 300,000 shares during the last quarter. Finally, FourWorld Capital Management LLC raised its position in Oncology Institute by 52.4% during the second quarter. FourWorld Capital Management LLC now owns 391,650 shares of the company’s stock valued at $803,000 after acquiring an additional 134,650 shares in the last quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on TOI shares. BTIG Research reissued a “buy” rating and issued a $7.00 target price on shares of Oncology Institute in a research report on Tuesday, October 21st. Needham & Company LLC started coverage on shares of Oncology Institute in a research note on Tuesday, November 25th. They issued a “buy” rating and a $5.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.50.

Insider Activity

In other Oncology Institute news, Director Brad Hively sold 13,333 shares of Oncology Institute stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $3.77, for a total value of $50,265.41. Following the transaction, the director directly owned 683,721 shares of the company’s stock, valued at $2,577,628.17. The trade was a 1.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mark L. Pacala sold 50,000 shares of the stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $4.00, for a total value of $200,000.00. Following the completion of the sale, the director directly owned 174,971 shares of the company’s stock, valued at $699,884. This represents a 22.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 63,580 shares of company stock valued at $251,145 in the last three months. 8.50% of the stock is owned by insiders.

Oncology Institute Trading Up 5.5%

NASDAQ TOI opened at $2.51 on Friday. The Oncology Institute, Inc. has a 1 year low of $0.60 and a 1 year high of $4.88. The company has a fifty day simple moving average of $3.34 and a 200 day simple moving average of $3.55. The company has a market cap of $246.93 million, a P/E ratio of -3.92 and a beta of 0.14.

Oncology Institute (NASDAQ:TOI) last released its earnings results on Thursday, November 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The firm had revenue of $136.56 million for the quarter, compared to analyst estimates of $122.63 million. Oncology Institute had a negative return on equity of 1,527.21% and a negative net margin of 13.21%.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.